V-Bio Ventures Portfolio company Biodol Therapeutics Reports on Ongoing Phase 1 Clinical Study in Healthy Volunteers for BDT272 for the Treatment of Pain Disorders 

Gent, Belgium. May 26^th 2025 – V-Bio Ventures portfolio company Biodol Therapeutics, a French biotech company developing next-generation pain treatments, reports on the Phase I clinical trial for its lead candidate, BDT272. This novel compound is a Negative Allosteric Modulator (NAM) targeting the interaction between the FLT3 receptor and its ligand FL, and is being developed for the treatment of various pain disorders. 

The first-in-human study is currently assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of BDT272 in healthy volunteers. The trial includes single ascending dose (SAD), multiple ascending dose (MAD), and food effect (FE) cohorts. So far, BDT272 is well tolerated at plasma exposures exceeding anticipated therapeutic exposures and has good pharmacokinetic properties. 

BDT272 is being developed for two oral treatment modalities: 

• As a non-opioid monotherapy for peripheral neuropathies such as Post-Herpetic Neuralgia (PHN), Painful Diabetic Peripheral Neuropathy (PDPN), or Chemotherapy-Induced Peripheral Neuropathy (CIPN). 

• As an adjuvant therapy for severe pain disorders requiring opioid treatment – including post-surgical pain and mixed nociceptive/inflammatory or inflammatory/neuropathic conditions – by enhancing morphine analgesia while preventing the development of morphine-induced tolerance, hyperalgesia, and avoiding respiratory depression or constipation. 

“Since our initial investment in BIODOL in 2020 we have witnessed the management team execute flawlessly on a plan to bring a new non-opioid pain treatment to patients.  Never losing sight of the ultimate goal of bringing new solutions to this significant unmet need, the team worked relentlessly to get BDT272 into the clinic.  I am very excited about where to company will be going next“ says Ward Capoen, Partner at V-Bio Ventures. 

“Since the inception of BIODOL, our team has been committed to translating this innovation from bench to bedside. Receiving regulatory authorization to begin this first-in-human trial marks a significant milestone after years of dedicated work,” said Fabien Granier, Chief Executive Officer of BIODOL Therapeutics. “With the Phase 1 study now underway, its completion will pave the way for proof-of-concept studies — a major source of hope for patients suffering from chronic pain conditions with few safe and effective treatment options”. 

About V-Bio Ventures 

V-Bio Ventures (www.v-bio.ventures) is an independent venture capital firm specialized in building and financing young, innovative life science companies. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the world’s premier life science institutes. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors.   

About Biodol Therapeutics 

Biodol Therapeutics (www.biodol.eu), founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. The company is focused on the development of allosteric inhibitors of the FLT3 receptor for the treatment of chronic pain. Biodol Therapeutics already owns the exclusive rights on a portfolio of 4 patents. The company has been supported by BPI France, Satt AxLR, Inserm Transfert, Region Occitanie, the French National Research Agency, SEMIA Incubator and Montpellier Business and Innovation Centre. 

__________________________________________________________________________________ 

For more information, please contact: 

Ward Capoen 

ward.capoen@v-bio.ventures